Modulating conjunctival wound healing.
Advances in molecular and cell biology have led to an expansion in our knowledge and understanding of the processes involved in wound healing. We review existing and potential therapies modulating the conjunctival scarring response, with particular reference to glaucoma filtration surgery. We discuss how the refinement of present antimetabolite regimens can minimise complications and improve surgical results, and advocate their use in carefully selected patient groups. Perhaps the most promising approach is targeting biological molecules. Hence, use of fully human neutralising monoclonal antibodies to the growth factor TGF beta has potential as a useful strategy for modifying conjunctival scarring. Combination therapies may also afford an improved therapeutic index. It is hoped that future therapies can offer safer, more specific, focal and titratable treatment, with far-reaching clinical applications.
Cordeiro
M F
MF
Department of Pathology & Glaucoma, Moorfields Eye Hospital, London, UK.
Chang
L
L
Lim
K S
KS
Daniels
J T
JT
Pleass
R D
RD
Siriwardena
D
D
Khaw
P T
PT
D000963:Antimetabolites / Q000494:pharmacology*; D002921:Cicatrix / Q000209:etiology / Q000517:prevention & control; D003228:Conjunctiva / Q000601:surgery*; D018463:Filtering Surgery / Q000009:adverse effects*; D005901:Glaucoma / Q000601:surgery*; D006801:Humans; D014945:Wound Healing / Q000187:drug effects* / Q000502:physiology
D000963:Antimetabolites